title: Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application.
abstract: Historically, oncology clinical trials have focused on comparing a new drug's efficacy to the standard of care. However, as our understanding of molecular pathways in oncology has evolved, so has our ability to predict how patients will respond to a particular drug, and thus comparison with a standard therapy has become less important. Biomarkers and corresponding diagnostic testing are becoming more and more important to drug development but also limit the type of patient who may benefit from the therapy. Newer clinical trial designs have been developed to assess clinically meaningful endpoints in biomarker-enriched populations, and the number of modern, molecularly driven clinical trials are steadily increasing. At the same time, barriers to clinical trial enrollment have also grown. Many barriers contribute to nonenrollment in clinical trials, including patient, physician, institution, protocol, and regulatory barriers. At the protocol level, eligibility criteria have become a large roadblock to clinical trial accrual. Over time, eligibility criteria have become more and more restrictive. To accrue an adequate number of patients to molecularly driven trials, we should consider eligibility criteria carefully and attempt to reduce restrictive criteria. Reducing restrictive eligibility criteria will allow more patients to be eligible for clinical trial participation, will likely increase the speed of drug approvals, and will result in clinical trial results that more accurately reflect treatment of the population in the clinical setting.
authors.affiliation: From the Department of Medicine, Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
authors.forename: Edward S
authors.initials: ES
authors.lastname: Kim
authors.affiliation: From the Department of Medicine, Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Atlas
authors.affiliation: From the Department of Medicine, Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
authors.forename: Gwynn
authors.initials: G
authors.lastname: Ison
authors.affiliation: From the Department of Medicine, Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Ersek
mesh_terms: D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D018579:Patient Selection